Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine

Gut

Volumn 53, Issue 11, 2004, Pages 1617-1623

  Kruis, W ^a,b   Fric P ^c   Pokrotnieks, J ^d   Lukas M ^e   Fixa, B ^e   Kascak M ^f   Kamm, M A ^g   Weismueller, J ^h   Beglinger, C ⁱ   Stolte, M ^j   Wolff, C ^a   Schulze, J ^a  

^a Evangelisches Krankenhaus Kalk   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c CENTRAL MILITARY HOSPITAL   (Czech Republic)

^d PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^e CHARLES UNIVERSITY   (Czech Republic)

^f Chirurgické oddelenie NsP   (Slovakia)

^g ST MARK S HOSPITAL   (United Kingdom)

^h St Mark's Hospital ^*

ⁱ INSTITUTE OF PATHOLOGY   (Germany)

^j Ardeypharm GmbH   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MESALAZINE; MUTAFLOR; PROBIOTIC AGENT; SALOFAK;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOSCOPY; ENTERITIS; ESCHERICHIA COLI; ESCHERICHIA COLI NISSLE 1917; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INTESTINE FLORA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; SIDE EFFECT; TREATMENT OUTCOME; ULCERATIVE COLITIS; VIRUS INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLITIS, ULCERATIVE; DOUBLE-BLIND METHOD; ESCHERICHIA COLI; FEMALE; HUMANS; MALE; MESALAMINE; MIDDLE AGED; PROBIOTICS; RECURRENCE; REMISSION INDUCTION;

EID: 4644239296     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2003.037747     Document Type: Article

References (43)

1. British Society of Gastroenterology. Clinical practice guidelines: inflammatory bowel disease, 1996. www.bsg.org.uk/clinical-prac/guidelines.htm.
2. Stange EF, Riemann J, von Herbay A, et al. Diagnosis and therapy of ulcerative colitis-results of an evidence-based consensus conference of the German Society of Digestive and Metabolic Diseases. Z Gastroenterol 2001;39:19-20.
3. Travis SP, Jewell DP. Salicylates for ulcerative colitis-their mode of action. Pharmacol Ther 1994;63:135-61.
4. Shanahan F. Probiotics and inflammatory bowel disease: is there a scientific rationale? Inflamm Bowel Dis 2000;6:107-15.
5. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998;114:262-7.
6. Sartor RB. Postoperative recurrence of Crohn's disease: The enemy is within the fecal stream. Gastroenterology 1998;114:398-400.
7. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995;108:1617-21.
8. Hulten K, Almashhrawi A, El Zaatari FA, et al. Antibacterial therapy for Crohn's disease: a review emphasizing therapy directed against mycobacteria. Dig Dis Sci 2000;45:445-56.
9. Hart AL, Stagg AJ, Kamm MA. Related articles, links use of probiotics in the treatment of inflammatory bowel disease. J Clin Gastroenterol 2003;36:111-19.
10. Kruis W, Schütz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-8.
11. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 1999;354:635-9.
12. Folwaczny C. Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment? Z Gastroenterol 2000;38:547-50.
13. Faubion WA, Sandborn WJ. Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad, Gastroenterology 2000;118:630-1.
14. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989;298:82-6.
15. Riley SA, Mani V, Goodman MJ, et al. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32:174-8.
16. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in inflammatory bowel disease. Gastroenterology 1989;96:804-10.
17. Farrington CP, Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference of non-unity relative risk. Stat Med 1990;9:1447-54.
18. Note for guidance on statistical principles for clinical trials. International conference on harmonisation. CPMP/ICH 363/96, 1998. http://www.emea.eu.int/pdfs/human/ich/036396en.pdf.
19. Sutherland LR, Roth DE, Beck PL. Alternatives to sulfosalazine: A meta-analysis of 5-ASA in the treatment of ulcerative colitis. Inflamm Bowel Dis 1997;3:65-78.
20. Riley SA. What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis? Gut 1998;42:761-3.
21. Sartor RB. Enteric microflora in IBD: pathogens or commensals? Inflamm Bowel Dis 1997;3:230-5.
22. Campieri M, Gionchetti P. Bacteria as the cause of ulcerative colitis. Gut 2001;48:132-5.
23. Hamilton-Miller JMT. A review of clinical trials of probiotics in the management of inflammatory bowel disease. Infect Dis Rev 2001;3:83-7.
24. Neish AS, Gewirtz AT, Zeng H, et al. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science 2000;289:1560-3.
25. Blum G, Marre R, Hacker J. Properties of Escherichia coli strains of serotype O6. Infection 1995;23:234-6.
26. Blum-Oehler G. The scanned bacterium: Analysis of the microbial genome. 4th Interdisciplinary Symposium: Internal microflora in symbiosis and pathogenicity. Berlin 2000. Hagen: Alfred-Nissle-Gesellschaft eV, 2001:23-31.
27. Grozdanov L, Zaehringer U, Blum-Oehler G, et al. A single-nucleotide exchange in the wzy gene is responsible for the semi-rough O6 LPS phenotype and serum sensitivity of Escherichia coli strain Nissle 1917. J Bacteriol 2002;184:5912-25.
28. Cukrowska B, Lodinova-Zadnikova R, Enders C, et al. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917. Scand J Immunol 2002;55:204-9.
29. Schulze J, Sonnenborn U. Oral administration of a certain strain of live Escherichia coli for intestinal disorders? Infection 1995;23:184-6.
30. Schulze J, Lorenz A, Mandel L. Colonisation of Escherichia coli in different gnotobiotic animal models. Microb Ecol Health Dis 1992;5:iv-v.
31. Oelschläger TA, Altenhoefer A, Hacker J. Inhibition of Salmonella typhimurium invasion into intestinal cells by the probiotic E. coli strain Nissle 1917. Gastroenterology 2001;120(suppl):A326.
32. Boudeau J, Rich C, France CF, et al. Escherichia coli strain Nissle 1917 inhibits adhesion to and invasion of intestinal epithelial cells by adherent-invasive E. coli isolated from a Crohn's disease patient. Gastroenterology 2001;120(suppl):A190.
33. Swidsinski A, Swidsinski S, Godzun A, et al. Therapy with E. coli Nissle reduces concentrations of mucosa associated colonic flora in patients with ulcerative colitis. Gastroenterology 2000;118(suppl):A1138.
34. Schulze J, Sonnenborn U. The role of the gut flora in inflammatory bowel diseases. In: Shimoyama T, Axon A, Lee A, et al, eds. In: Helicobacter meets inflammatory bowel disease. Tokyo: Medical Tribune Inc, 2002:393-417.
35. Möllenbrink M, Bruckschen E. Treatment of chronic constipation with physiologic Escherichia coli bacteria. Results of a clinical study of the effectiveness and tolerance of microbiological therapy with the E. coli Nissle 1917 strain (Mutaflor). Med Klin 1994;89:587-93.
36. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997;25:653-8.
37. Bruckschen E, Horosiewicz H. Chronic constipation. Comparision of microbiological therapy and lactulose. MMW 1994;136:241-5.
38. Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002;51:405-9.
39. Guslandi M, Mezzi G, Sorghi M, et al. Saccharomyces baulardii in maintenance treatment of Crohn's disease. Dig Dis Sci 2000;45:1462-4.
40. Kuzela L, Kaščák M, Vavrecka A. Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pauchitis. Am J Gastroenterol 2001;96:3218-19.
41. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003;124:1202-9.
42. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pauchitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119:305-9.
43. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the foecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999;13:1103-8.